CLL Latest Treatments: Conversation with Specialist, Dr. Kerry Rogers | The Patient Story

Dr. Kerry Rogers shares the latest news and opinions on treatment options for CLL (chronic lymphocytic leukemia) patients.

Lending her vast expertise and research experience as an assistant professor in the Division of Hematology at The Ohio State University (OSUCCC – James), specializing in chronic lymphocytic leukemia (CLL) and hairy cell leukemia (HCL), Dr. Rogers sheds light on participating in clinical trials and the community’s efforts to move the mark in the standard of care.

Explore below for Dr. Rogers’ insights on everything from the latest in CLL treatment, decision making throughout treatment, importance, and prospects of clinical trials.

TIME CODES:
[0:22] Introduction: Dr. Kerry Rogers
[2:30] What is CLL
[4:06] Stages of CLL, Rai Staging, Tests for CLL (IgHV mutational status, FISH test for CLL)
[7:58] CLL in layman’s terms
[10:15] Standard CLL Treatment, Shifting Away from Chemotherapy, Rise of Targeted Therapy
[14:10] How long have the targeted agents been in use
[16:31] Continuous novel agent therapy vs. time-limited, treatment for relapsed/refractory (R/R) CLL, BTK inhibitors, venetoclax
[19:48] Targeted Therapy Side Effects
[24:38] Triple Therapy (Ibrutinib, Venetoclax, Obinutuzumab)
[28:32] Metrics for these studies, determining resistance to treatment
[31:26] Importance of clinical trials
[33:48] Misconceptions about clinical trials and “placebos”
[34:44] CAR T cell therapy
[36:46] Reversible BTK inhibitors
[38:26] Treatments for Hairy Cell Leukemia (HCL), purine analogue chemotherapy, new drugs (cladribine, pentostatin, vemurafenib), prognosis and findings so far